Abbvie (ABBV) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Abbvie (ABBV) do?
Abbvie Inc (ABBV) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Discovers, manufactures, and markets specialty prescription medications for autoimmune disorders, cancers, and neurological conditions. Manufactures and sells patented biologic therapies, blood cancer treatments, and aesthetic injectables through global. It is worth $501.19B on the market and sold $66.03B over the last year.
- Market cap
- $501.19B
- P/E ratio
- 48.8×
- Annual sales
- $66.03B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 08, 2026
Brands and businesses behind ABBV
- Skyrizi: Treats plaque psoriasis and inflammatory bowel diseases, generating revenue through prescription sales and pharmacy benefit reimbursements.
- Rinvoq: Treats rheumatoid arthritis and atopic dermatitis, earning revenue through ongoing outpatient prescription drug sales.
- Botox: Provides therapeutic and cosmetic neurotoxin injections, generating recurring revenue from medical clinics, dermatologists, and plastic surgeons.
- Humira: Treats multiple inflammatory conditions, generating revenue through global pharmacy prescriptions despite competition from lower-cost biosimilar copies.
- Venclexta: Treats specific adult blood cancers, earning revenue from hospital and specialty pharmacy sales.
- Juvederm: Provides hyaluronic acid dermal fillers, earning wholesale revenue from aesthetic medical practices and licensed clinicians.
ABBV’s flags, in plain English
Each flag is a number from Abbvie’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.
Wide Gross Margin
Gross margin of 73.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earnings Jumping
Profits up 40.1% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Runway Is Short
This year's bills are bigger than the cash and assets on hand to pay them. At its current rate of spending, its cash on hand covers only a limited stretch.
2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about ABBV
How big is Abbvie?
Abbvie’s market cap is $501.19B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $66.03B: what customers paid the company over the last year, before any costs.
What is ABBV’s P/E ratio?
ABBV’s P/E ratio is 48.8×. Investors pay about 48.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ABBV?
Expired patents on Humira continue to reduce sales as cheaper biosimilar alternatives capture market share. That is one risk on Abbvie’s card. Its first risk flag is Runway Is Short, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Abbvie’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ABBV’s filings on SEC.gov. The Margin Monkey is research, not advice.
